INTRODUCTION
Over the past 25 years, human papillomavirus (HPV) has been shown to be an important cause of oropharyngeal cancers (OPCs) in many world regions, with the great majority of HPV-driven OPC being caused by HPV type 16 (HPV-16). 1 HPV currently is overtaking tobacco exposure as the leading cause of OPC in some countries with a high human development index, including the United States and some European and Latin American countries, in which both the incidence rate of OPC and the attributable fraction (AF) of HPV are rising. 2 In the United States, the incidence of OPC currently is greater than that of cervical cancer, a consequence of the increasing incidence of OPC as well as reductions in the incidence of cervical cancer due to the success achieved by screening. 3 This shift highlights the need for parallel preventive measures. Nevertheless, arguments against additional research regarding HPV-driven OPC screening have been made and include the promise of primary prevention through HPV vaccination, 4 the currently low incidence rates, 5 and favorable outcomes with current therapy compared with non-HPV-driven head and neck cancers. 6 The lack of an identifiable clinical precursor lesion, insufficient diagnostic technology with which to detect small lesions, and the absence of de-escalated clinical management for patients with early-stage cancer or precancer are current barriers to screening for OPC. This article is not intended to address all the questions related to the validity and timeliness of screening for HPV-driven OPC but instead to raise important questions, guide discussions, highlight deficits and/or confusion in the existing literature, and propose needed steps in the research agenda. The following general aspects of a screening program are considered 7 and applied to HPV-driven OPC: 1) a sufficiently high incidence, either in the general population or an enriched high-risk population; 2) a sensitive and specific screening tool or biomarker; 3) appropriate methods for accurately diagnosing the cancer (or precancer) among individuals who screen positive; 4) effective treatment for patients with early-stage lesions; and 5) evidence of mortality and/or morbidity reductions.
INCIDENCE AND SURVIVAL RATES FOR OPC
In the United States, the age-adjusted incidence of OPC in the Surveillance, Epidemiology, and End Results (SEER) program among individuals aged 50 years was 7.4 per 100,000 person-years in 2013, being nearly 5-fold higher in men (12.8 per 100,000 person-years) compared with women (2.7 per 100,000 person-years). 8 Incidence rates have increased dramatically over the past decades, by up to 4% per year among some birth cohorts of men, in whom age-adjusted incidence rates exceed 20 per 100,000 person-years 5 ; these increases in OPC incidence were observed primarily among white men. The overwhelming majority of OPC cases currently are caused by HPV-16 infections. 9 Prophylactic HPV vaccines are not expected to curtail these trends in the coming decades because vaccination was not recommended for boys until 2009 and therefore will not impact OPC rates for multiple decades until the vaccinated cohorts attain ages at which the OPC risk increases (nb, the median age at the time of diagnosis of HPV-driven OPC is 53 years). 10 For boys in the United States aged 13 to 17 years, coverage with at least 1 dose of the HPV vaccine was 56% as of 2016. 11 If vaccination rates among women are sufficiently high to induce herd immunity, 12, 13 oral HPV infection rates in men may decrease beyond what is expected from direct vaccination. 14 We projected OPC incidence rates among white men aged 50 years for the period 2015 through 2030, when none of the vaccinated cohorts will yet age into the risk set, using a Poisson model based on observed data from SEER during 2000 through 2014. This analysis projects noteworthy incidence rates of OPC in HPVunvaccinated US white men over the coming decades ( Fig. 1 ) (see Supporting Information Fig. 1 ).
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SCREENING TOOLS AND BIOMARKERS FOR HPV-DRIVEN OPC
Researchers have investigated biomarkers for HPVdriven OPC, including HPV detection in oral samples and HPV antibodies in serum/plasma (Table 1) . 17, 18 The detection of HPV in oral samples may be attractive as a research tool because noninvasive mouthwash and gargle specimens are simple to obtain. However, in a routine clinical setting, obtaining a blood sample is standard procedure. Furthermore, the detection of HPV in the oral cavity is more likely an exposure assessment than a (future) disease assessment, whereas antibodies against HPV-16 oncoproteins are more likely a disease marker that occurs later in the pathway from HPV infection to cancer. Oral cytology, akin to cervical cancer screening methods, has been ruled out as a possibility due to its low yield and inability to access the target region (ie, the tonsils or base of the tongue). 19, 20 Characteristics of the oral HPV detection test
Several case series and case-control studies have compared HPV detection in oral samples with HPV status of tumors, and in cases compared with controls. To our knowledge, these studies have focused on HPV DNA testing and not intact viral particle testing, viral integration, RNA detection, or other assays that may better reflect viral persistence and its potential to cause cancer.
In focusing on recent studies with an adequate sample size, HPV DNA detection in oral rinse samples among patients with HPV-driven tumors (ie, biomarker sensitivity) ranged from 30% to 77%; the range when restricted to HPV-16 was 45% to 82%. [21] [22] [23] [24] This extreme heterogeneity in estimates is likely driven by multiple factors, including different sampling protocols and HPV detection methods, which thus far rely on research-based assays that are run in multiple laboratories and likely have differing test characteristics. 4) ; oropharynx, not otherwise specified (C10.9); pharynx, not otherwise specified (C14.0); and Waldeyer's ring (C14.2). Observed data from the Surveillance, Epidemiology and End Results 18 registries (2000 Results 18 registries ( -2014 were used to assess whether a significant change in the slope of incidence rate trends occurred using Joinpoint software. 15 Only 1 significant joinpoint was identified (men aged 50-54 years in 2007); in this case, the time period starting in that year was used in the forecasting models. Incidence rates were log-linearly projected during 2015 through 2030 using predicted values derived from Poisson models. The observed and projected incidence rates were plotted on a log 10 scale. No human papillomavirusvaccinated birth cohorts were included above; projections ceased at 2030. In addition to projecting incidence rates using age-specific estimates, strong and statistically significant age, period, and cohort effects were observed using the National Cancer Institute's Age-Period-Cohort Analysis Tool (https:// analysistools.nci.nih.gov/apc). 16 After adjusting for age and period, OPC rates were found to increase across birth cohorts through the 1920s to the 1950s before plateauing among birth cohorts in the 1960s and 1970s. Based on this analysis, it is anticipated that future rates of OPC will continue to increase.
In studies comparing HPV DNA detection in oral rinse samples with HPV detection in the tonsils, the concordance is poor. 20, 25 In a recent study by Combes et al, the percentage positive agreement in HPV-16 status between oral rinse and direct tonsil brushing ex vivo was <10%, suggesting that oral HPV status does not accurately represent HPV status in the biological site of interest. 20 In a pooled prospective nested case-control study, cases and controls from the American Cancer Society Cancer Prevention Study II Nutrition Cohort and the National Cancer Institute Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial were combined to evaluate oral HPV and risk of OPC (irrespective of the HPV status of the tumor). Oral HPV-16 prevalence was detected in approximately 20% of OPC cases an average of 6 years before diagnosis and in 1% of controls; thus, oral HPV-16 detection increased the risk of OPC by 22-fold after adjustment for covariates. Although this elevation in risk among cases is exciting for confirming the association between oral HPV infection and OPC risk, it would likely not be sufficiently discriminative to translate to a stand-alone screening marker. 26 
Specificity of Oral HPV Detection in Individuals Without Diagnosed Cancer
To the best of our knowledge, the largest study to date concerning oral HPV prevalence is a population-based study in the United States that demonstrated the prevalence of oral HPV-16 to be 1.0% in healthy individuals, 27 which translates into a biomarker specificity of approximately 99%. When the outcome was expanded to consider all carcinogenic HPV types, the prevalence was 3.7% and therefore the marker specificity was 96.3%. To our knowledge, there are no prospective studies that translated detection of oral HPV and risk of incident OPC (ie, positive predictive value [PPV] of the marker), indicating a current research gap.
HPV-16 E6 seropositivity
The potential for HPV-16 E6 positivity to be used to identify individuals at higher risk of OPC was initially reported in the European Prospective Investigation into Cancer and Nutrition (EPIC) study 17 and later confirmed in PLCO, 18 2 large cohort studies in Europe and the United States, respectively. In these studies, HPV-16 E6 antibodies were present an average of 6 to 7 years before the cancer diagnosis, and were robust and stable even among study participants diagnosed with OPC >10 years after blood collection. The time point of seroconversion in the natural history of these cancers at which the immune system recognizes the viral protein(s) and elicits an antibody response is unknown, given the lack of serial prediagnostic blood samples from existing studies/registries, although it appears to be at least 10 years before diagnosis. This long lead time could allow for the identification of a very large percentage of future patients with OPC with only a single blood draw. These discoveries were based on an HPV-16 E6 assay developed at the German Cancer Research Center 28 that now has been applied in multiple, global epidemiological studies. Another HPV serologic assay may be promising. 29 Having multiple valid and reproducible assays would be an advantage to the field. However, different serological assays, even those HPV-Driven OPC Screening Considerations/Kreimer et al Cancer May 1, 2018 that target the same protein, may demonstrate important differences in test characteristics, as has been shown for virus-like particle enzyme-linked immunoadsorbent assay. 30 Thus, future biomarkers must be rigorously evaluated, ideally as part of an international proficiency study.
Sensitivity of HPV-16 E6 Seropositivity in Predicting Invasive OPC Tumors
In the EPIC and PLCO studies, HPV-16 E6 seropositivity in prediagnostic serum samples of patients with OPC was approximately 30% and 50%, respectively, 17, 18 which was similar to the AF of HPV-positive OPC tumors during the study time periods in both cohorts. Specifically, HPV-16 E6 seroprevalence in OPC cases in the EPIC study (33%) was the same as the AF of HPV-16 identified in tumor samples from a European-wide study conducted at a similar point in time (the Alcohol-Related Cancers and Genetics Susceptibility 'ARCAGE' Study). 31 In the PLCO trial, a small subset of tumor specimens (n59) was retrieved, all of which were found to be concordantly HPV-16 driven and HPV-16 E6 seropositive (ie, 100% sensitive), or not HPV-16 driven and HPV-16 E6 seronegative (ie, 100% specific). Complementary studies that evaluated the sensitivity of the biomarker against HPV DNA plus p16 immunohistochemistry and/ or HPV RNA status in tumors (ie, using gold standard methods for determining whether a tumor is caused by HPV infection) confirmed the high sensitivity (90%). [32] [33] [34] [35] There is a suggestion that the test characteristics of other assays may be similarly high. 36 Using a binaryclassifier algorithm involving all HPV-16 early antigens in a case-control study, the sensitivity was reported to be 85% and the specificity was 99% 36 ; a caveat to using casecontrol studies is that they typically have later-stage cancers, which consequently could inflate test characteristics; the goal of screening is to identify patients with early-stage cancers or precancers. Thus, independent evaluation and validation in prospective cohorts is important. Given that these data currently are available only for the German Cancer Research Center assay, the remainder of this article will focus on results utilizing that assay.
Specificity of HPV-16 E6 Seropositivity in Individuals Without Diagnosed Cancer
In a pooled analysis, HPV-16 E6 seropositivity in >4500 cancer-free individuals was found to be 0.7%, translating into a specificity of 99.3% 37 ; the population in this assessment consisted of the controls from case-control studies and therefore was overwhelmingly male and older, representative of the OPC population. To our knowledge, no population-based estimates of HPV-16 E6 seropositivity currently exist, which constitutes a gap in research.
However, few HPV-16 E6-seropositive individuals eventually will develop HPV-driven cancer. In our current understanding, seroconversion to E6 would be the result of an overexpressed oncoprotein (ie, an early lesion, which may be as small as a few cells). Thus, it remains to be determined whether, at the time of seroconversion, individuals can mount a cytotoxic T-cell response that eliminates those cells overexpressing E6 before tumors can develop.
PPV and Negative Predictive Value of HPV-16 E6 Seropositivity
In PLCO, the HPV-16 E6 biomarker analysis was nested within a cohort study, therefore enabling estimation of the 10-year cumulative risk of OPC by HPV-16 E6 serology status. Among predominantly white men in the United States aged 50 to 70 years, those who were HPV-16 E6 seropositive were found to have a 10-year risk of OPC of 6.2% (range, 1.8%-21.5%). 18 We do note that this cohort had a relatively low incidence of OPC. Specifically, using data from 1994 through 2009 among white men aged 50 to 84 years, the standardized incidence ratio for OPC in the PLCO trial compared with SEER 13, standardized by 5-year age group and 4-year calendar period, was 0.57 (37 observed and 65 expected cases). This would suggest the true cumulative 10-year risk may have been underestimated. Nevertheless, the PPV most likely does not exceed 1% per year, which clearly would result in a high excess of negative screens. The observed 10-year risk of any OPC among HPV-16 E6-seronegative individuals was 0.03%; even if this is an underestimate, if an individual screened negative for HPV-16 E6 at the time of enrollment into the cohort, their risk of OPC was remarkably low.
Target Population for Screening
Although individuals who are seronegative for HPV-16 E6 have a low risk of developing HPV-driven OPC, a serology test applied to the general population still would result in a large number of false-positive screens. Identifying a subgroup at higher risk of HPV-16-driven OPC therefore would be important to further improve the PPV of the serology marker. On the basis of current incidence rates and trends, it would appear sensible to restrict potential screening to men in countries in which a high percentage of OPC cases are attributable to HPV-16, and either high or increasing incidence. The restriction to men is Commentary because there is a low burden of HPV-driven OPC reported in women. 5, 8 We currently are investigating whether other HPV-16 antigens (eg, E2) or demographic, genetic, 38 or environmental factors (eg, smoking) contribute to additional risk stratification for HPV-driven OPC, and whether the inclusion of behavioral markers may achieve risk stratification for patients with head and neck cancers overall.
Future Research of Biomarkers That Achieve Risk Stratification
More data on HPV detection in oral samples and HPV antibodies in serum samples are needed (Table 1) . 17, 18 For the detection of oral HPV, there are strong data on the population prevalence from the National Health and Nutrition Examination Survey (NHANES), which covers a broad age range and includes analysis of sexual behaviors. Nevertheless, we lack a good understanding of oral HPV as a risk predictor because, to our knowledge, it has been evaluated prospectively only once. 24 HPV-16 E6 serology also has research gaps; to our knowledge, there are no population-based prevalence estimates or even investigations among healthy individuals in cohort studies. Importantly, because oral HPV and HPV serology are the leading candidates for biomarkers, a direct comparison is needed in which the 2 biomarkers are measured simultaneously in the same population. Finally, as new biomarkers for HPV-driven OPC are developed, scientists are encouraged to follow the "phases of biomarker development" described by Pepe et al in 2001 39 or, at a minimum, document noninferiority to biomarkers that already have navigated these steps.
Key Features for Future Research
Given the incidence of OPC, marker specificity must be exceptionally high (>99%) to ensure that the negative predictive value of the biomarker will be sufficiently high in the population to be screened to reduce the number of individuals with false-positive results who require additional diagnostic procedures. 40 The setting for the evaluation of the biomarker also is critical because the burden of HPV-driven OPC, dictated in this situation not only by disease incidence but also the AF of HPV causing the cancer will drive the PPV of the marker.
As a thought exercise, we considered the effect of varying the disease burden (incidence * AF) and assay characteristics on the impact of PPV, the number needed to screen to find 1 case, and the number of false-positive screens. Scenarios are based on a single 1-time screen (Table 2) . In scenario 1, we assumed a marker sensitivity of 100% and a specificity of 99.5%, a tested population of 100,000 with an OPC incidence of 20 per 100,000 screened, and an HPV-16 AF of 80% (a scenario similar to white males in the United States). Although the computed PPV would be 3.2%, the number needed to screen to find 1 case would be high, and the number of falsepositive screens would be considerable, this is the most promising of the scenarios. If the incidence or AF were lower (scenario 2), in this example 10 per 100,000 screened and 10%, respectively, the PPV would drop to 0.2% and 100,000 individuals would be needed to find a single case (similar to countries in Central and Southern Europe). Finally, if the prevalence and AF were high (20 per 100,000 and an HPV-16 AF of 80%) but the marker sensitivity was only 50% (scenario 3), the number needed to screen would be very high, similar to oral HPV-16 DNA detection in oral rinse samples. Based on this thought exercise, the onus is on the investigator to ensure sufficient disease burden, AF, and marker characteristics to warrant investigation of marker natural history and screening potential, to avoid causing undue harm to study participants.
DIAGNOSTICS
Screening is predicated on a diagnostic strategy that identifies disease at an earlier stage than it otherwise would be detected, with the goal of improved survival. In instances where survival already is high, such as HPV-driven OPC, reduced morbidity may be the goal. Currently, clinical screening is not possible due to missing critical pieces of knowledge, including the natural history of tonsillar HPV infection to the development of OPC, and the shortcomings of the diagnostic modalities currently available. OPC typically is not detected until it is clinically evident in a lymph node, and rarely is isolated to the oropharynx. These primary tumors arise in the crypts of the lymphoid tissue and are asymptomatic. Furthermore, a preneoplastic lesion (eg, dysplasia or carcinoma in situ) for HPVrelated OPC is not an entity that is recognized pathologically, although one is believed to exist. 41 Current clinical examination and imaging techniques have limitations in the oropharynx, even within the setting of pathologic disease such as an HPV-positive metastatic lymph node without a clinically evident primary site, which raises concerns in the setting of a healthy population. Positron emission tomography scans have high sensitivity, but are particularly limited when focusing on lymphoid tissue, the native tissue in which these cancers arise. Thus, diagnostic techniques with improved sensitivity to detect early invasive lesions are needed. Novel imaging techniques, such as transcervical ultrasound and narrow band imaging, have shown promise in the detection of primary tumors in cases in which traditional imaging techniques have failed, 42, 43 but additional research regarding subsequent steps after a positive test are needed to determine whether screening is feasible.
TREATMENT OF EARLY (NONSYMPTOMATIC) LESIONS
In the absence of resolving the diagnostic dilemma (ie, the ability to identify a primary lesion), are there therapeutic strategies that could serve to reduce cancer risk? For example, in women with cervical precancer, excision of the cervical transformation zone nearly eliminates risk of progression to cervical cancer. Indeed, retrospective data have suggested that tonsillectomy (removal of the relevant lymphoid tissue and associated epithelium) reduces the risk of OPC. 44, 45 While tonsillectomy was associated with decreased odds of tonsillar cancer, increased odds of cancer of the base of the tongue were reported. 46 In addition, tonsillectomy has its own inherent risks (life-threatening or catastrophic bleeding), and therefore optimizing the ability to predict the patient's risk of developing HPVdriven OPC becomes paramount, as does demonstrating that the benefits outweigh the harms (including considerations of quality of life and cost-effectiveness). Other exciting therapeutic approaches in high-risk populations include a therapeutic HPV vaccine. 47 Indeed, should efficacious therapeutic vaccines with minimal side effects become available, they may provide an opportunity to treat HPV-16 E6-seropositive individuals and prevent the development of invasive OPC tumors. Other strategies may include immune checkpoint inhibitors, which have shown promise in the treatment of patients with recurrent/metastatic head and neck malignancies. 48 Given the favorable long-term survival of patients with HPV-16-driven OPC, 49, 50 there is interest in decreasing therapeutic intensity with the goal of reducing potential long-term sequelae of therapy. [51] [52] [53] These strategies currently are being explored using several therapeutic modalities (eg, upfront surgery, chemoselection, reduced radiotherapy dose, immunotherapy, etc); available data to date have suggested that survival may not be compromised, yet quality of life measures are improved. Currently, morbidity due to the treatment of OPC is extensive. 54 Some of the more severe complications include speech and swallowing dysfunction, feeding tube dependence, disfigurement/body image alterations, physiologic distress, depression, lack of nutrition/resumption of normal diet, mucositis, and infectious complications. Because these survivors of OPC hopefully will live for decades after treatment, the goal of screening would be to increase early-stage detection, which in turn would reduce treatment morbidity, improve posttreatment quality of life, and further improve survival.
EVALUATION OF OPC SCREENING IMPACT ON MORBIDITY AND MORTALITY
If and when the preceding challenges are solved, a trial likely will be needed before widespread implementation of OPC screening can be considered. Initially, a stepwise approach may be more appropriate, first to define the natural history of a potential biomarker and then to evaluate its efficacy in the process of screening for HPV-driven OPC. A large evaluation likely would be needed to account for the current rarity of the outcome. For example, if rates of OPC among white men at high risk are 25 per 100,000 screened, it stands to reason that one would need to prospectively study 100,000 men to obtain a sufficient number of events for the workup of screeningpositive individuals and identify precancer/early-stage cancer. Serial samples from prospective studies will be important to evaluate whether changes in biomarker levels are relevant for screening. In addition, assessing the efficacy of screening as well as the risks and harms of the screening process also would need to be captured to later weigh these against the potential gains.
CONCLUSIONS HPV-driven OPC typically presents at a later stage with lymph node involvement. Nevertheless, long-term survival remains relatively high. This raises the question of whether screening and earlier detection would result in further improvements in survival. A more realistic goal may be to reduce treatment morbidity if early detection results in the focused identification of symptom-free individuals at increased risk of OPC, who then receive less invasive therapy. The question remains: will screening for HPVdriven OPC be possible in the future? We currently lack the tools for the evidence-based implementation of OPC screening. Additional discussion and research are needed to clarify whether a risk algorithm could create a high-risk screening population. From there, we could envision using an HPV biomarker to detect those at highest risk of HPV-driven OPC. The HPV-16 E6 serology biomarker is a candidate; other biomarkers will need to document noninferiority before researchers move forward with natural history studies. We need to define the outcome (lesion) for the screening; a study of HPV-16 E6 antibodies in a cohort study most likely would make it feasible to identify and describe the yet-unknown precursor lesion to HPVdriven OPC by enriching a study population with those at higher risk of having undiagnosed OPC. Finally, we do not yet know how to follow subjects with a positive screening test for OPC. Advances in diagnostics and the prophylactic treatment of early lesions, and documentation that an OPC screening program improves OPCrelated outcomes, also are necessary.
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